These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

913 related articles for article (PubMed ID: 17476345)

  • 1. Altered macrophage differentiation and immune dysfunction in tumor development.
    Sica A; Bronte V
    J Clin Invest; 2007 May; 117(5):1155-66. PubMed ID: 17476345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology of tumor-associated macrophages.
    Yuan A; Chen JJ; Yang PC
    Adv Clin Chem; 2008; 45():199-223. PubMed ID: 18429498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance.
    Allavena P; Sica A; Garlanda C; Mantovani A
    Immunol Rev; 2008 Apr; 222():155-61. PubMed ID: 18364000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer related inflammation: the macrophage connection.
    Sica A; Allavena P; Mantovani A
    Cancer Lett; 2008 Aug; 267(2):204-15. PubMed ID: 18448242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
    Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
    J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.
    Ugel S; De Sanctis F; Mandruzzato S; Bronte V
    J Clin Invest; 2015 Sep; 125(9):3365-76. PubMed ID: 26325033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophages in cancer and infectious diseases: the 'good' and the 'bad'.
    Porta C; Riboldi E; Totaro MG; Strauss L; Sica A; Mantovani A
    Immunotherapy; 2011 Oct; 3(10):1185-202. PubMed ID: 21995571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
    Kawai O; Ishii G; Kubota K; Murata Y; Naito Y; Mizuno T; Aokage K; Saijo N; Nishiwaki Y; Gemma A; Kudoh S; Ochiai A
    Cancer; 2008 Sep; 113(6):1387-95. PubMed ID: 18671239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-released microvesicles as vehicles of immunosuppression.
    Valenti R; Huber V; Iero M; Filipazzi P; Parmiani G; Rivoltini L
    Cancer Res; 2007 Apr; 67(7):2912-5. PubMed ID: 17409393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth.
    al-Sarireh B; Eremin O
    J R Coll Surg Edinb; 2000 Feb; 45(1):1-16. PubMed ID: 10815374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated macrophages: foe or accomplice of tumors?
    Ohno S; Suzuki N; Ohno Y; Inagawa H; Soma G; Inoue M
    Anticancer Res; 2003; 23(6a):4395-409. PubMed ID: 14666727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives for antitumor therapy based on the recognition mechanism by which macrophages identify undesirable foreign and native cells and molecules.
    Takiguchi K; Inagawa H; Nishizawa T; Kohchi C; Soma G
    Anticancer Res; 2002; 22(6C):4277-80. PubMed ID: 12553069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender dimorphism of macrophage response to GMCSF and IL-4 for differentiation into dendritic cells.
    Gupta V; Singh SM
    Am J Reprod Immunol; 2008 Jul; 60(1):43-54. PubMed ID: 18593437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppressive influences in the immune response to cancer.
    Bronte V; Mocellin S
    J Immunother; 2009 Jan; 32(1):1-11. PubMed ID: 19307988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling the macrophage invasion of tumours: effects on growth and composition.
    Owen MR; Sherratt JA
    IMA J Math Appl Med Biol; 1998 Jun; 15(2):165-85. PubMed ID: 9661282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of tumor-associated macrophage in malignant tumors: should the location of the infiltrated macrophages be taken into account during evaluation?
    Ohno S; Inagawa H; Soma G; Nagasue N
    Anticancer Res; 2002; 22(6C):4269-75. PubMed ID: 12553068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capitalizing on the immunogenicity of dying tumor cells.
    Fonseca C; Dranoff G
    Clin Cancer Res; 2008 Mar; 14(6):1603-8. PubMed ID: 18347160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.
    Marigo I; Dolcetti L; Serafini P; Zanovello P; Bronte V
    Immunol Rev; 2008 Apr; 222():162-79. PubMed ID: 18364001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological properties of interleukin 2 and its role in pathogenesis of selected diseases--a review.
    Olejniczak K; Kasprzak A
    Med Sci Monit; 2008 Oct; 14(10):RA179-89. PubMed ID: 18830208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.